Every day, thousands of biopharmaceutical researchers and patients go boldly to fight the odds to unearth cutting-edge medicines and cures.
Patients with a wide range of life-threatening and debilitating illnesses today live in the hope tomorrow will bring a new medicine that will improve or even save their life. America’s Biopharmaceutical Companies are researching and developing new medicines to meet unmet need and continuing research and development even after U.S. Food and Drug Administration (FDA) approval, all with the goal of improving patients’ health, quality of life, and saving lives.
Since 2000, nearly 900 new medicines have been approved by the FDA, helping patients live longer, healthier lives. Among the remarkable new treatments reaching patients are the first gene therapies for devastating rare genetic disorders impacting infants and children, curative treatments for hepatitis C, a range of CAR-T cell therapies driving unprecedented remission rates for cancer patients as well as immunotherapies and targeted therapies widely regarded as driving accelerated drops in cancer mortality for U.S. patients in recent years.
Explore the medicines in development
Biopharmaceutical research and development is key to improving patients’ health and saving lives. America’s Biopharmaceutical Companies are tireless in the pursuit of revolutionary treatments and vaccines. Thanks to the innovative medicines they’ve developed, patients all over the world are living longer, healthier and more productive lives. Together, we stand committed to treat and defend against disease in all its forms.
Research does not end once a medicine is approved by the FDA; it is built upon to improve outcomes for patients, simplify treatment regimens and monitor safety. America's Biopharmaceutical Companies are committed to a dynamic research ecosystem that delivers safe and efficacious treatments to patients.